Moclobemide in continuation treatment of major depressive episodes: an open follow-up study over six months.

Abstract

This was an open study of moclobemide, 300 to 450 mg daily, as continuation treatment for 18 weeks, after a 6-week randomized, double-blind acute treatment period with moclobemide administered in three different dosage regimens. The primary antidepressant efficacy criterion was the total score on the Hamilton Rating Scale for Depression. Secondary efficacy… (More)

Topics

  • Presentations referencing similar topics